FDA Orders Suicide Warnings On Epilepsy Drugs

Law360, New York (December 17, 2008, 12:00 AM EST) -- Epilepsy drugs must now be labeled with warnings about the risk of suicidal thoughts and behavior associated with the medications, the U.S. Food and Drug Administration announced Wednesday.

Epilepsy-drug makers will also be required to submit risk evaluation and mitigation reports that include a medication guide for patients with information about suicide risks associated with anti-epileptic drugs, the FDA said.

The new labeling requirement will affect all anti-epileptic drugs, including Carbatrol, Klonopin, Tranxene, Depakote, Zarontin, Paganone, Felbatol, Neurontin, Lamictal, Vimpat, Keppra, Mesantoin, Celotin, Trileptal, Lyrica, Topamax,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.